目的 进一步明确转录信号转导子与激活子3(signal transducers and activators of transcription 3, STAT3)信号通路在调节乳腺癌多柔比星耐药中的作用,促进转录信号转导子与激活子3信号通路抑制剂在逆转肿瘤耐药方面的临床应用。方法 首先在临床乳腺癌组织标本水平,应用Western blotting检测转录信号转导子与激活子3与活化磷酸化转录信号转导子与激活子3(phosphorylated STAT3, pSTAT3)的表达水平,同时应用RT-PCR及Western blotting检测转录信号转导子与激活子3/磷酸化转录信号转导子与激活子3在乳腺癌敏感及耐药细胞中的表达水平;再应用小分子干扰RNA(small interfering RNA, siRNA)技术阻断转录信号转导子与激活子3表达,通过Western blotting方法检测转录信号转导子与激活子3-小分子干扰RNA对转录信号转导子与激活子3表达的影响;最后分别应用细胞免疫荧光法和四甲基偶氮唑蓝法,检测阻断转录信号转导子与激活子3表达后,乳腺癌细胞的增殖活性及IC50值,从而观察转录信号转导子与激活子3-小分子干扰RNA是否能够抑制乳腺癌细胞增殖,以及能否增强乳腺癌细胞对多柔比星的敏感性。结果 转录信号转导子与激活子3/磷酸化转录信号转导子与激活子3在肿瘤组织以及在多柔比星敏感及耐药的乳腺癌细胞中均呈现高水平表达,并且在多柔比星耐药乳腺癌细胞中的表达高于在相应敏感细胞中的表达水平。转录信号转导子与激活子3-小分子干扰RNA明显下调转录信号转导子与激活子3蛋白表达,并抑制了敏感乳腺癌细胞的生长。转录信号转导子与激活子3-小分子干扰RNA和多柔比星联合应用后,与单独应用多柔比星比较,使多柔比星耐药乳腺癌细胞的IC50降低了4倍,同时抑制了转录信号转导子与激活子3信号通路介导的抗凋亡蛋白的表达。结论 转录信号转导子与激活子3信号通路活化与乳腺癌发生相关,在多柔比星耐药乳腺癌细胞中显著活化,阻断乳腺癌多柔比星耐药细胞中转录信号转导子与激活子3信号通路可提高其对多柔比星的敏感性,并促进细胞凋亡。本试验为探索阻断转录信号转导子与激活子3信号通路逆转肿瘤耐药的可行性,以及临床联合应用转录信号转导子与激活子3抑制剂与化疗药物克服肿瘤细胞多药耐药现象提供实验基础。
Abstract
OBJECTIVE To further define the modulation effect of signal transducers and activators of transcription 3 (STAT3) in adriamycin-resistant breast cancer and to promote the clinical application of the inhibitors of STAT3 in reversing multidrug resistance in cancer. METHODS Firstly, the levels of STAT3 and phosphorylated STAT3 (pSTAT3) expression in clinical breast cancer tissue samples were determined by Western blotting. The expression of STAT3 and pSTAT3 in adriamycin-sensitive and adriamycin-resistant breast cancer cell lines was evaluated by RT-PCR and Western blotting. Secondly, the expression of STAT3 was detected by Western blotting after blocking the STAT3 signal pathway with small interfering RNA targeting STAT3 (STAT3-siRNA). Finally, after the expression of STAT3 was blocked by STAT3-siRNA, immunofluorescence was performed to study the proliferation activity of breast cancer cells and MTT was used to determine the IC50 of the cells in order to observe whether STAT3-siRNA had any inhibitory effects on the growth of breast cancer cells and whether it could promote the efficacy of adriamycin in breast cancer cells. RESULTS STAT3 and pSTAT3 were highly expressed both in clinical breast cancer tissue samples and in adriamycin-sensitive-and-resistant breast cancer cells. The expression of pSTAT3 in adriamycin-resistant breast cancer cells was significantly higher than in adriamycin-sensitive breast cancer cells. STAT3-siRNA conspicuously decreased the expression of STAT3 protein and inhibited the growth of adriamycin-sensitive breast cancer cells. Compared with the single application of adriamycin, IC50 of adriamycin-resistant breast cancer cells decreased by 4 fold when adriamycin was used in combinaiton with STAT3-siRNA. Meanwhile, an inhibition of the expression of the anti-apoptotic protein mediated by STAT3 was observed in adriamycin-resistant breast cancer cells. CONCLUSION This study reveals that the development of breast cancer is related to the activation of STAT3. The activation of STAT3 in adriamycin-resistant breast cancer cells was more notable than in adriamycin-sensitive cells. The inhibition of the STAT3 pathway could improve the adriamycin sensitivity of adriamycin-resistant breast cancer cells and lead to their apoptosis. The RESULTS of this study explores the feasibility of the reversal of drug resistance in cancer by blocking STAT3 pathway and establishes the experimental basis for promoting the clinical use of the inhibitors of STAT3 pathway and the chemotherapeutics to overcome the multidrug resistance in cancer.
关键词
转录信号转导子与激活子3 /
乳腺癌 /
耐药 /
多柔比星 /
小分子干扰RNA
{{custom_keyword}} /
Key words
signal transducers and activators of transcription 3 /
breast cancer /
drug resistance /
adriamycin /
small interfering RNA
{{custom_keyword}} /
中图分类号：
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] MA X T. The research progress of signal transducers and activators of transcription 3 and the tumor drug resistance [J]. Cancer Res Prev Treat,2011,38(4):474-475.
[2] ZHAO M, JIANG B, GAO F H. Small molecule inhibitors of STAT3 for cancer therapy [J]. Curr Med Chem, 2011, 18(26):4012-4018.
[3] ZHANG X L, ZHANG J, ZHANG C, et al. Experimental therapy of tumor by blockade of transcription factor Stat3 activation via induction of apoptosis and reversing of multidrug resistance [C]. Xi′an:The 6th Congress of the Chinese Society of Immunology, 2008:138-139.
[4] WANG T X, WANG Y Y, ZHANG Z Q. Small interfering RNA targeting STAT3 enhances antitumor activity of doxorubicin [J]. Acta Pharm Sin(药学学报),2013, 48 (1):52-58.
[5] LIU A, LIU Y, JIN Z, et al. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells [J]. PLoS One, 2012, 7 (10):e46624.
[6] ZHOU J, ONG C N, HUR G M, et al. Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin [J]. Biochem Pharmacol, 2010, 79 (9):1242-1250.
[7] FALAMARZIAN A, ALIABADI H M, MOLAVI O, et al. Effective down-regualtion of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy [J]. J Biomed Mater Res A, 2014, 102 (9):3216-3218.
[8] GARIBOLDI M B, RAVIZZA R, MOLTENI R, et al. Inhibition of STAT3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line [J]. Cancer Lett, 2007, 258(2):181-188.
[9] SIEGEL R, NAISHADHAM D, JEMAL A, et al. Cancer statistics, 2012 [J]. CA Cancer J Clin, 2012, 62(1):10-29.
[10] LACERDA L, PUSZTAI L, WOODWARD W A, et al. The role of tumor initiating cells in drug resistance of breast cancer:implication for future therapeutic approaches [J]. Drug Resist Updat, 2010, 13(4-5):99-108.
[11] YUQI G, JEFFREY N, COLIN O, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer [J]. Clin Cancer Res, 2010, 16(23):5759-5769.
[12] KEINOSUKE R, EDWIN C, CAO Y, et al. Activation of signal transducer and activator of transcription 3 (STAT3) pathway in osteosarcoma cells and overexpression of phosphorylated-STAT3 correlates with poor prognosis [J]. J Orthop Res, 2010, 28(7):971-978.
[13] CAO Y, JOSEPH H S, ANDREW J, et al. A novel target for treatment of chordoma:signal transducers and activators of transcription 3 [J]. Mol Cancer Ther, 2009, 8(9):2597-2605.
[14] ZHENFENG D, RACHEL Y A, MEAGAN R, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and STAT3 phosphorylation in multi-drug resistant ovarian cancer cells [J]. Cancer Chemother Pharmacol, 2009, 63(4):681-689.
[15] GUO Y, NEMETH J, O′BRIEN C, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer [J]. Clin Cancer Res, 2010, 16 (23):5759-5769.
[16] CAO Y, JOSEPH H S, ANDREW J S, et al. A novel target for treatment of chordoma:signal transducers and activation of transcription 3 [J]. Mol Cancer Ther, 2009, 8 (9):2597-2605.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
河南省卫生厅医学科技攻关计划资助项目(201303013)
{{custom_fund}}
PDF(2383 KB)
